| Substance | Condition | Seq | Src | PMID | Dtl | Title |
| Astragalosides | Acute Liver Injury | 2 | PM | 37113780 | 📋 | Astragaloside IV attenuates lipopolysaccharide induced liver injury by modulating Nrf2-mediated oxidative stress and NLRP3-mediated inflammation |
| Astragalosides | Acute Liver Injury | 1 | PM | 27938564 | 📋 | [Protective Effect of Astragaloside IV Against Acute Liver Failure in Experimental Mice] |
| Astragalosides | Acute Pancreatitis | 1 | PM | 25604657 | 📋 | Astragaloside IV ameliorates acute pancreatitis in rats by inhibiting the activation of nuclear factor-κB |
| Astragalosides | Cholestasis | 3 | PM | 36339578 | 📋 | Astragalus saponins and its main constituents ameliorate ductular reaction and liver fibrosis in a mouse model of DDC-induced cholestatic liver disease |
| Astragalosides | Cholestasis | 1 | PM | 33307056 | 📋 | Metabolomics Analysis Delineates the Therapeutic Effects of Huangqi Decoction and Astragalosides on α-naphthylisothiocyanate (ANIT) -Induced Cholestasis in Rats |
| Astragalosides | Cholestasis | 4 | PM | 29056006 | 📋 | [Mechanism of Astragaloside prevents cholestatic liver fibrosis through inhibition of Notch signaling activation] |
| Astragalosides | Cholestasis | 2 | PM | 25917841 | 📋 | Astragaloside prevents BDL-induced liver fibrosis through inhibition of notch signaling activation |
| Astragalosides | Colitis | 2 | PM | 34246191 | 📋 | Suppression of plasmacytoid dendritic cell migration to colonic isolated lymphoid follicles abrogates the development of colitis |
| Astragalosides | Colitis | 1 | PM | 28951595 | 📋 | Astragaloside II Promotes Intestinal Epithelial Repair by Enhancing L-arginine Uptake and Activating the mTOR Pathway |
| Astragalosides | Colitis | 3 | PM | 28150820 | 📋 | Astragaloside IV ameliorates 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis implicating regulation of energy metabolism |
| Astragalosides | Colon Cancer | 1 | PM | 31456687 | 📋 | Astragaloside III Enhances Anti-Tumor Response of NK Cells by Elevating NKG2D and IFN-γ |
| Astragalosides | Colorectal Cancer | 8 | PM | 38230773 | 📋 | Astragaloside IV regulates circ_0001615 and miR-873-5p/LASP1 axis to suppress colorectal cancer cell progression |
| Astragalosides | Colorectal Cancer | 7 | PM | 37793276 | 📋 | The potential molecular pathways of Astragaloside-IV in colorectal cancer: A systematic review |
| Astragalosides | Colorectal Cancer | 6 | PM | 37776619 | 📋 | Astragaloside IV inhibits AOM/DSS-induced colitis-associated tumorigenesis via activation of PPARγ signaling in mice |
| Astragalosides | Colorectal Cancer | 5 | PM | 33095374 | 📋 | Astragaloside IV Exerts Anti-tumor Effect on Murine Colorectal Cancer by Re-educating Tumor-Associated Macrophage |
| Astragalosides | Colorectal Cancer | 2 | PM | 30468676 | 📋 | Astragaloside IV Inhibits Human Colorectal Cancer Cell Growth |
| Astragalosides | Colorectal Cancer | 3 | PM | 29710520 | 📋 | Astragaloside IV Inhibits Cell Proliferation of Colorectal Cancer Cell Lines Through Down-Regulation of B7-H3 |
| Astragalosides | Colorectal Cancer | 4 | PM | 29041002 | 📋 | Astragaloside IV Induced miR-134 Expression Reduces EMT and Increases Chemotherapeutic Sensitivity by Suppressing CREB1 Signaling in Colorectal Cancer Cell Line SW-480 |
| Astragalosides | Colorectal Cancer | 1 | PM | 28281965 | 📋 | Astragaloside IV Enhances Cisplatin Chemosensitivity in Human Colorectal Cancer via Regulating NOTCH3 |
| Astragalosides | Constipation | 3 | PM | 38289380 | 📋 | Single-cell RNA sequencing reveals cellular dynamics and therapeutic effects of astragaloside IV in slow transit constipation |
| Astragalosides | Constipation | 2 | PM | 38074145 | 📋 | Astragaloside IV improves slow transit constipation by regulating gut microbiota and enterochromaffin cells |
| Astragalosides | Constipation | 1 | PM | 32628809 | 📋 | Astragaloside IV alleviates mouse slow transit constipation by modulating gut microbiota profile and promoting butyric acid generation |
| Astragalosides | Dysbiosis | 2 | PM | 34438030 | 📋 | Hypoglycemic effect of astragaloside IV via modulating gut microbiota and regulating AMPK/SIRT1 and PI3K/AKT pathway |
| Astragalosides | Dysbiosis | 1 | PM | 32628809 | 📋 | Astragaloside IV alleviates mouse slow transit constipation by modulating gut microbiota profile and promoting butyric acid generation |
| Astragalosides | Gastric Cancer | 6 | PM | 37708965 | 📋 | Astragaloside IV inhibits pathological functions of gastric cancer-associated fibroblasts through regulation of the HOXA6/ZBTB12 axis |
| Astragalosides | Gastric Cancer | 4 | PM | 35435117 | 📋 | Astragaloside IV exhibits anti-tumor function in gastric cancer via targeting circRNA dihydrolipoamide S-succinyltransferase (circDLST)/miR-489-3p/ eukaryotic translation initiation factor 4A1(EIF4A1) pathway |
| Astragalosides | Gastric Cancer | 3 | PM | 34124983 | 📋 | Protective role of astragaloside IV in gastric cancer through regulation of microRNA-195-5p-mediated PD-L1 |
| Astragalosides | Gastric Cancer | 1 | PM | 29775897 | 📋 | The Gastric Mucosal Protective Effects of Astragaloside IV in MNNG-Induced GPL Rats |
| Astragalosides | Gastric Cancer | 2 | PM | 29577459 | 📋 | Astragaloside IV Reverses MNNG-induced Precancerous Lesions of Gastric Carcinoma in Rats: Regulation on Glycolysis Through miRNA-34a/LDHA Pathway |
| Astragalosides | Gastric Cancer | 5 | PM | 29358859 | 📋 | Astragaloside IV inhibits pathological functions of gastric cancer-associated fibroblasts |
| Astragalosides | Gastric Motility Disorders | 1 | PM | 38074145 | 📋 | Astragaloside IV improves slow transit constipation by regulating gut microbiota and enterochromaffin cells |
| Astragalosides | Gastric Ulcer | 2 | PM | 38762925 | 📋 | Astragaloside IV ameliorates indomethacin-induced intestinal inflammation in rats through inhibiting the activation of NLRP3 inflammasome |
| Astragalosides | Gastric Ulcer | 1 | PM | 26845156 | 📋 | Gastroprotective Effects of Astragaloside IV Against Acute Gastric Lesion in Rats |
| Astragalosides | Gastritis | 1 | PM | 27816726 | 📋 | Astragaloside IV Protects Rat Gastric Mucosa Against Aspirin-Induced Damage |
| Astragalosides | Hepatic Cirrhosis | 1 | PM | 30651810 | 📋 | Astragaloside IV Combating Liver Cirrhosis Through the PI3K/Akt/mTOR Signaling Pathway |
| Astragalosides | Hepatic Fibrosis | 7 | PM | 36339578 | 📋 | Astragalus saponins and its main constituents ameliorate ductular reaction and liver fibrosis in a mouse model of DDC-induced cholestatic liver disease |
| Astragalosides | Hepatic Fibrosis | 5 | PM | 33787592 | 📋 | Evaluation of astragaloside IV in hepatic fibrosis: A meta-analysis |
| Astragalosides | Hepatic Fibrosis | 4 | PM | 31900718 | 📋 | Astragaloside IV Synergizes With Ferulic Acid to Alleviate Hepatic Fibrosis in Bile Duct-Ligated Cirrhotic Rats |
| Astragalosides | Hepatic Fibrosis | 3 | PM | 31641375 | 📋 | Astragaloside IV Regulates NF-κB-mediated Cellular Senescence and Apoptosis of Hepatic Stellate Cells to Suppress PDGF-BB-induced Activation |
| Astragalosides | Hepatic Fibrosis | 1 | PM | 29853950 | 📋 | Astragaloside Inhibits Hepatic Fibrosis by Modulation of TGF- β 1/Smad Signaling Pathway |
| Astragalosides | Hepatic Fibrosis | 9 | PM | 29056006 | 📋 | [Mechanism of Astragaloside prevents cholestatic liver fibrosis through inhibition of Notch signaling activation] |
| Astragalosides | Hepatic Fibrosis | 2 | PM | 28245465 | 📋 | Astragaloside Alleviates Hepatic Fibrosis Function via PAR2 Signaling Pathway in Diabetic Rats |
| Astragalosides | Hepatic Fibrosis | 11 | PM | 28147890 | 📋 | Astragaloside IV synergizes with ferulic acid to suppress hepatic stellate cells activation in vitro |
| Astragalosides | Hepatic Fibrosis | 10 | PM | 27196295 | 📋 | Huangqi decoction alleviates dimethylnitrosamine-induced liver fibrosis: An analysis of bile acids metabolic mechanism |
| Astragalosides | Hepatic Fibrosis | 12 | PM | 26220342 | 📋 | Astragaloside IV suppresses transforming growth factor-β1 induced fibrosis of cultured mouse renal fibroblasts via inhibition of the MAPK and NF-κB signaling pathways |
| Astragalosides | Hepatic Fibrosis | 6 | PM | 25917841 | 📋 | Astragaloside prevents BDL-induced liver fibrosis through inhibition of notch signaling activation |
| Astragalosides | Hepatic Fibrosis | 8 | PM | 23459070 | 📋 | Astragaloside IV suppresses collagen production of activated hepatic stellate cells via oxidative stress-mediated p38 MAPK pathway |
| Astragalosides | Hepatic Ischemia-Reperfusion | 1 | PM | 21693217 | 📋 | Astragaloside IV protects against ischemia reperfusion in a murine model of orthotopic liver transplantation |
| Astragalosides | Hepatic Steatosis | 3 | PM | 36155217 | 📋 | Astragaloside IV ameliorates diet-induced hepatic steatosis in obese mice by inhibiting intestinal FXR via intestinal flora remodeling |
| Astragalosides | Hepatic Steatosis | 2 | PM | 35264962 | 📋 | Astragaloside IV Relieves Atherosclerosis and Hepatic Steatosis via MAPK/NF-κB Signaling Pathway in LDLR -/- Mice |
| Astragalosides | Hepatic Steatosis | 1 | PM | 33708118 | 📋 | Astragaloside IV Improves High-Fat Diet-Induced Hepatic Steatosis in Nonalcoholic Fatty Liver Disease Rats by Regulating Inflammatory Factors Level via TLR4/NF-κB Signaling Pathway |
| Astragalosides | Inflammatory Bowel Disease | 1 | PM | 34589089 | 📋 | Astragaloside IV Alleviates the Experimental DSS-Induced Colitis by Remodeling Macrophage Polarization Through STAT Signaling |
| Astragalosides | Intestinal Injury | 2 | PM | 31817362 | 📋 | Astragaloside IV Protects Against Oxidative Stress in Calf Small Intestine Epithelial Cells via NFE2L2-Antioxidant Response Element Signaling |
| Astragalosides | Intestinal Injury | 1 | PM | 28951595 | 📋 | Astragaloside II Promotes Intestinal Epithelial Repair by Enhancing L-arginine Uptake and Activating the mTOR Pathway |
| Astragalosides | Intestinal Metaplasia | 1 | PM | 29775897 | 📋 | The Gastric Mucosal Protective Effects of Astragaloside IV in MNNG-Induced GPL Rats |
| Astragalosides | Intestinal Mucositis | 1 | PM | 36610133 | 📋 | Astragaloside IV alleviates cytarabine-induced intestinal mucositis by remodeling macrophage polarization through AKT signaling |
| Astragalosides | Intestinal Permeability | 2 | PM | 38689349 | 📋 | Blockade of PI3K/AKT signaling pathway by Astragaloside IV attenuates ulcerative colitis via improving the intestinal epithelial barrier |
| Astragalosides | Intestinal Permeability | 1 | PM | 35571132 | 📋 | Astragaloside IV Alleviates Intestinal Barrier Dysfunction via the AKT-GSK3β-β-Catenin Pathway in Peritoneal Dialysis |
| Astragalosides | Irritable Bowel Syndrome | 1 | PM | 28951595 | 📋 | Astragaloside II Promotes Intestinal Epithelial Repair by Enhancing L-arginine Uptake and Activating the mTOR Pathway |
| Astragalosides | Liver Cancer | 15 | PM | 38835015 | 📋 | Astragaloside IV inhibits cell viability and glycolysis of hepatocellular carcinoma by regulating KAT2A-mediated succinylation of PGAM1 |
| Astragalosides | Liver Cancer | 17 | PM | 37894415 | 📋 | Astragaloside IV Attenuates Programmed Death-Ligand 1-Mediated Immunosuppression during Liver Cancer Development via the miR-135b-5p/CNDP1 Axis |
| Astragalosides | Liver Cancer | 13 | PM | 37301185 | 📋 | Amelioratory effects of astragaloside IV on hepatocarcinogenesis via Nrf2-mediated pSmad3C/3L transformation |
| Astragalosides | Liver Cancer | 12 | PM | 35422920 | 📋 | Astragaloside IV inhibits the progression of liver cancer by modulating macrophage polarization through the TLR4/NF-κB/STAT3 signaling pathway |
| Astragalosides | Liver Cancer | 11 | PM | 35092472 | 📋 | Astragaloside IV suppresses migration and invasion of TGF-β 1-induced human hepatoma HuH-7 cells by regulating Nrf2/HO-1 and TGF-β 1/Smad3 pathways |
| Astragalosides | Liver Cancer | 10 | PM | 34157326 | 📋 | Astragaloside IV inhibits hepatocellular carcinoma by continually suppressing the development of fibrosis and regulating pSmad3C/3L and Nrf2/HO-1 pathways |
| Astragalosides | Liver Cancer | 2 | PM | 32417721 | 📋 | Astragaloside IV Suppresses Development of Hepatocellular Carcinoma by Regulating miR-150-5p/β-catenin Axis |
| Astragalosides | Liver Cancer | 6 | PM | 32259679 | 📋 | Astragaloside IV Enhances Cisplatin Chemosensitivity in Hepatocellular Carcinoma by Suppressing MRP2 |
| Astragalosides | Liver Cancer | 5 | PM | 32111763 | 📋 | Astragaloside IV Induces Apoptosis, G 1-Phase Arrest and Inhibits Anti-apoptotic Signaling in Hepatocellular Carcinoma |
| Astragalosides | Liver Cancer | 3 | PM | 30463823 | 📋 | Apoptosis and Antitumor Effects Between β-elemene and Astragaloside and Drug Mechanism Analysis |
| Astragalosides | Liver Cancer | 9 | PM | 28713943 | 📋 | Astragaloside IV Downregulates the Expression of MDR1 in Bel‑7402/FU Human Hepatic Cancer Cells by Inhibiting the JNK/c‑Jun/AP‑1 Signaling Pathway |
| Astragalosides | Liver Cancer | 4 | PM | 28266023 | 📋 | Astragaloside II Sensitizes Human Hepatocellular Carcinoma Cells to 5-fluorouracil via Suppression of Autophagy |
| Astragalosides | Liver Cancer | 1 | PM | 28179291 | 📋 | Synergistic Inhibitory Effect of Traditional Chinese Medicine Astragaloside IV and Curcumin on Tumor Growth and Angiogenesis in an Orthotopic Nude-Mouse Model of Human Hepatocellular Carcinoma |
| Astragalosides | Liver Cancer | 7 | PM | 28112375 | 📋 | Astragaloside IV Inhibits Metastasis in Hepatoma Cells Through the Suppression of Epithelial-Mesenchymal Transition via the Akt/GSK-3β/β-catenin Pathway |
| Astragalosides | Liver Cancer | 16 | PM | 25934513 | 📋 | Compound Astragalus and Salvia miltiorrhiza extracts modulate MAPK-regulated TGF-β/Smad signaling in hepatocellular carcinoma by multi-target mechanism |
| Astragalosides | Liver Cancer | 8 | PM | 23146037 | 📋 | Reversal of P-glycoprotein-mediated Multidrug Resistance of Human Hepatic Cancer Cells by Astragaloside II |
| Astragalosides | Liver Cancer | 14 | PM | 20126993 | 📋 | Proteomic characterization of the cellular response to chemopreventive triterpenoid astragaloside IV in human hepatocellular carcinoma cell line HepG2 |
| Astragalosides | Liver Damage | 1 | PM | 33846768 | 📋 | Astragaloside IV alleviates liver injury in type 2 diabetes due to promotion of AMPK/mTOR‑mediated autophagy |
| Astragalosides | MAFLD | 5 | PM | 36155217 | 📋 | Astragaloside IV ameliorates diet-induced hepatic steatosis in obese mice by inhibiting intestinal FXR via intestinal flora remodeling |
| Astragalosides | MAFLD | 4 | PM | 33953586 | 📋 | Astragaloside IV Alleviates Liver Inflammation, Oxidative Stress and Apoptosis to Protect Against Experimental Non-Alcoholic Fatty Liver Disease |
| Astragalosides | MAFLD | 3 | PM | 33157223 | 📋 | Astragaloside IV Inhibits Protein Tyrosine Phosphatase 1B and Improves Insulin Resistance in Insulin-Resistant HepG2 Cells and Triglyceride Accumulation in Oleic Acid (OA)-treated HepG2 Cells |
| Astragalosides | MAFLD | 2 | PM | 29713279 | 📋 | Astragaloside IV Inhibits Triglyceride Accumulation in Insulin-Resistant HepG2 Cells via AMPK-Induced SREBP-1c Phosphorylation |
| Astragalosides | MAFLD | 1 | PM | 28344322 | 📋 | Astragaloside IV Attenuates Free Fatty Acid-Induced ER Stress and Lipid Accumulation in Hepatocytes via AMPK Activation |
| Astragalosides | Necrotizing Enterocolitis | 2 | PM | 37413858 | 📋 | Astragaloside IV regulates TL1A and NF-κB signal pathway to affect inflammation in necrotizing enterocolitis |
| Astragalosides | Necrotizing Enterocolitis | 1 | PM | 27698775 | 📋 | Astragaloside IV Ameliorates Necrotizing Enterocolitis by Attenuating Oxidative Stress and Suppressing Inflammation via the Vitamin D3-upregulated Protein 1/NF-κB Signaling Pathway |
| Astragalosides | Ulcerative Colitis | 5 | PM | 38689349 | 📋 | Blockade of PI3K/AKT signaling pathway by Astragaloside IV attenuates ulcerative colitis via improving the intestinal epithelial barrier |
| Astragalosides | Ulcerative Colitis | 4 | PM | 35752072 | 📋 | Astragaloside Ⅳ alleviates ulcerative colitis by regulating the balance of Th17/Treg cells |
| Astragalosides | Ulcerative Colitis | 3 | PM | 35178991 | 📋 | [Effects of astragaloside Ⅳ on inflammatory response and percentage of peripheral blood Th17 cells in mice with ulcerative colitis] |
| Astragalosides | Ulcerative Colitis | 1 | PM | 31814910 | 📋 | Astragaloside II Alleviates the Symptoms of Experimental Ulcerative Colitis in vitro and in vivo |
| Astragalosides | Ulcerative Colitis | 2 | PM | 31572532 | 📋 | Astragaloside IV Alleviates the Symptoms of Experimental Ulcerative Colitis in vitro and in vivo |
